COVID-19: debate with the pharmaceutical industry 

Stqarrija 
COVI 
 
 

Aqsam din il-paġna ma' ħaddieħor: 

MEPs will have a second discussion with representatives from pharmaceutical companies that worked on developing vaccines and therapeutics during the COVID-19 pandemic.

When: Monday, 10 October 2022, 14.30 – 18.30

Where: European Parliament in Brussels, Altiero Spinelli, room 3G2

Parliament’s special committee on COVID-19 (COVI) will hold a second debate with five pharmaceutical industry representatives:

  • Janine Small, President of International Developed Markets, Pfizer
  • Dr Franz-Werner Haas, Chief Executive Officer, CureVac
  • Stanley Erck, Chief Executive Officer, Novavax
  • Roger Connor, President Global Vaccines, Glaxo Smith Kline
  • Carlos Montañés, Executive Vice-President, HIPRA

They will share their views on past and present manufacturing, distribution and equitable access to COVID-19 vaccines and therapeutics. The debate is likely to focus on the work to develop vaccines for new variants, the authorisation process, transparency of contracts, as well as measures to ensure access to COVID-19 vaccines and treatments for low- and middle-income countries.

The full agenda is available here.

You can watch the debate live here.

Background

In March 2022, the European Parliament established a new “Special committee on the COVID-19 pandemic: lessons learned and recommendations for the future” (COVI). The committee’s work focuses on four areas: health, democracy and fundamental rights, social and economic impact, as well as global aspects related to the pandemic.

On 5 September 2022, COVI organised a first debate with the pharmaceutical industry (representatives from Gilead Sciences, Sanofi, AstraZeneca and Moderna).

Kuntatti: 

 

Further information 

 

Informazzjoni dwar il-prodott 

Ref.:  20221003IPR42120